Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles

Hypertension

Volumn 44, Issue 6, 2004, Pages 935-943

  Zhang, Cuihua ^a   Hein, Travis W ^a   Wang, Wei ^a   Miller, Matthew W ^b   Fossum, Theresa W ^b   McDonald, Michelle M ^b   Humphrey, Jay D ^c   Kuo, Lih ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c Texas A and M University   (United States)

Author keywords

Arginine; Hypertension; Microcirculation; Nitric oxide synthase; Vasodilation

Indexed keywords

ADENOSINE; ARGINASE; ARGININE; N(G) HYDROXYARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA COARCTATION; ARTERIOLE; ARTERY DILATATION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; UPREGULATION; VASODILATATION;

ANIMALS; ARGINASE; ARTERIOLES; CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; HYPERTENSION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; SWINE; UP-REGULATION; VASODILATION;

EID: 9644282852     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000146907.82869.f2     Document Type: Article

References (42)

1. Luscher TF, Richard V, Tschudi M, Yang ZH, Boulanger C. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol. 1990;15:519-527.
2. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens. 2001;19:1245-1254.
3. Mitchell BM, Dorrance AM, Webb RC. GTP cyclohyrdolase 1 downregulation contributes to glucocorticoid hypertension in rats. Hypertension. 2003;41:669-674.
4. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Hollad SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.
5. Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, Zakopoulos N, Kotsis V, Dagre AG, Stamatelopoulos K, Protogerou A, Stamatelopoulos SF. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol. 2002;86:317-323.
6. Susic D, Francischetti A, Frohlich ED. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension. 1999;33:451-455.
7. Asab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, Schwartz D, Cabili S, Silverberg D, Iaina A. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995;47:1515-1521.
8. Ono H, Ono Y, Frohlich ED. L-arginine reverses nephrosclerosis in aged spontaneously hypertensive rats. J Hypertens. 1999;17:121-128.
9. Tousoulis D, Antoniades C, Tentolouris C, Goumas G, Stefanadis C, Toutouzas P. L-arginine in cardiovascular disease: dream or reality? Vasc Med. 2002;7:203-211.
10. Wu G, Meininger CJ. Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am J Physiol. 1995;269:H1312-H1318.
11. G-hydroxy-L-arginine during high-output NO production. Am J Physiol. 1996;271:H1988-H1998.
12. Zhang C, Hein TW, Wang W, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001;15:1264-1266.
13. Hein TW, Zhang C, Wei W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003;17:2328-2330.
14. Rodriguez S, Richert L, Berthelot A. Increased arginase activity in aorta of mineralcorticoid-salt hypertensive rats. Clin Exp Hypertens. 2000;22:75-85.
15. Sahach VF, Baziliuk OV, Kotsiuruba AV, Buzhanevich OM. Disorders of endothelium-dependent vascular reactions and of the arginase and NO-synthase pathways of L-arginine metabolism in arterial hypertension. Fiziol Zh. 2000;46:3-13.
16. Fossum TW, Baltzer WI, Miller MW, Aguirre M, Whitlock D, Solter P, Makarski LA, McDonald MM, An MY, Humphrey JD. A novel aortic coarctation model for studying hypertension in the pig. J Invest Surg. 2003;16:35-44.
17. Kuo L, Davis MJ, Chilian WM. Myogenic activity in isolated subepicardial and subendocardial coronary arterioles. Am J Physiol. 1988;255:H1558-H1562.
18. Kuo L, Chilian WM, Davis MJ. Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am J Physiol. 1991;261:H1706-H1715.
19. Selamnia M, Mayeur C, Robert V, Blachier F. α- Difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol. 1998;55:1241-1245.
20. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide. 1999;3:427-438.
21. Moali C, Boucher JL, Renodon-Corniere A, Stuehr DJ, Mansuy D. Oxidations of N(omega)-hydroxyarginine analogues and various N-hydroxyguanidines by NO synthase II: key role of tetrahydrobiopterin in the reaction mechanism and substrate selectivity. Chem Res Toxicol. 2001;14:202-210.
22. ATP channels. Circ Res. 1999;85:634-642.
23. Hein TW, Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ Res. 1998;83:404-414.
24. Hein TW, Kuo L. oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles. Am J Physiol Heart Circ Physiol. 2000;278:H175-H183.
25. Kalkman EA, Bilgin YM, van Haren P, van Suylen RJ, Saxena PR, Schoemaker RG. Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic banding. Cardiovasc Res. 1996;32:1088-1095.
26. Marcus ML, Mueller TM, Gascho JA, Kerber RE. Effects of cardiac hypertrophy secondary to hypertension on the coronary circulation. Am J Cardiol. 1979;44:1023-1028.
27. Jeremy RW, Fletcher PJ, Thompson J. Coronary pressure-flow relations in hypertensive left ventricular hypertrophy. Comparison of intact autoregulation with physiological and pharmacological vasodilation in the dog. Circ Res. 1989;65:224-236.
28. Schwartzkopff B, Mundhenke M, Strauer BE. Remodelling of intramyocardial arterioles and extracellular matrix in patients with arterial hypertension and impaired coronary reserve. Eur Heart J. 1995;16:82-86.
29. Wei LH, Jacobs AT, Morris SM Jr., Ignarro LJ. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2000;279:C248-C256.
30. Nishimura H, Rosenblum WI, Nelson GH, Boynton S. Agents that modify EDRF formation alter antiplatelet properties of brain arteriolar endothelium in vivo. Am J Physiol. 1991;261:H15-H21.
31. Sun D, Messina EJ, Koller A, Wolin MS, Kaley G. Endothelium-dependent dilation to L-arginine in isolated rat skeletal muscle arterioles. Am J Physiol. 1992;262:H1211-H1216.
32. Frame MD, Sarelius IH. L-arginine-induced conducted signals alter upstream arteriolar responsivity to L-arginine. Circ Res. 1995;77:695-701.
33. Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA, Cannon RO III. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 1997;30:1220-1227.
34. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol 1996;114:107-132.
35. Bouloumie A, Bauersachs J, Linz W, Scholkens BA, Wiemer G, Fleming I, Busse R. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 1997;30:934-9411.
36. Bauersachs J, Bouloumie A, Mulsch A, Wiemer G, Fleming I, Busse R. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc Res. 1998;37:772-779.
37. Wirtz PH, Von Kanel R, Frey K, Ehlert U, Fischer JE. Glucocorticoid sensitivity of circulating monocytes in essential hypertension. Am J Hypertens. 2004;17:489-494.
38. Unger T. Blood pressure lowering and rennin-angiotensin system blockade. J Hypertens. 2003;6:S3-S7.
39. Zhang DX, Yi FX, Zou AP, Li PL. Role of ceramide in TFN-alpha-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. Am J Physiol Heart Circ Physiol. 2002;283:H1785-H1794.
40. 2 receptors in modulating coronary microvascular function. Circ Res. 2003;92:322-329.
41. Nelin L, Nash H, Chicoine, L. Cytokine treatment increases arginine metabolism and uptake in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1232-L1239.
42. Kotsiuruba AV, Svishchenko IeP, Bukhanevich OM, Kosiakova HV, Berdyshev AH, Radchenko VV, Mishchenko LA, Hula NM. Effect of irbesartan-angiotensin II type I receptor inhibitor on oxidative metabolism of lipids in essential hypertension. Fiziol Zh. 2002;48:22-28.